APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Results of Operations and Financial Condition

APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Results of Operations and Financial Condition
Item 9.01 and Item 9.01, including the attached Exhibits 99.1 and 99.2,is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Story continues below

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Aptevo Therapeutics Inc. Exhibit
EX-99.1 2 apvo-ex991_253.htm EX-99.1 apvo-ex991_253.htm Exhibit 99.1   Aptevo Therapeutics Highlights Key 2019 Priorities ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia;APVO210 Beginning Phase 1 Clinical Trial in Q1 2019;ALG.APV-527 Progressing with CTA Submission in H2 2019 Projecting 1/3 Cash Burn Reduction in 2019 Launching New Growth Initiatives for IXINITY SEATTLE,…
To view the full exhibit click here


Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).

An ad to help with our costs